Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute, discusses the challenges with finding biomarkers for immunotherapy agents.
ctDNA Monitoring in Breast Cancer Treatment: Early Signs and Future Directions
Mridula George, MD, discussed a study investigating ctDNA monitoring during neoadjuvant therapy of breast cancer.
Read More
Navigating the Landscape of Immunotherapy Toxicities
Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.
Listen
FDA ODAC Votes Unanimously to Mandate Phase Assessments in NSCLC Perioperative Regimens
The FDA’s Oncologic Drugs Advisory Committee convened to assess the need for rigorous trial designs evaluating perioperative regimens in resectable non–small cell lung cancer.
Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy
In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.
Immunotherapy for Angiosarcoma: Promising Results for Scalp and Face Tumors
Juneko Grilley-Olson, MD, discussed findings from a phase 2 study investigating the addition of immunotherapy to chemotherapy for the treatment of advanced angiosarcoma.
Beyond Docetaxel: Adagrasib Shows Promise in KRAS G12C-Mutant NSCLC
Robert Jotte, MD, PhD, discussed findings from the phase 3 KRYSTAL-12 study evaluating adagrasib vs docetaxel in previously treated KRAS G12C-mutated non–small cell lung cancer.